189 related articles for article (PubMed ID: 28203284)
1. Novel emerging treatments for hepatitis C infection: a fast-moving pipeline.
Kardashian AA; Pockros PJ
Therap Adv Gastroenterol; 2017 Feb; 10(2):277-282. PubMed ID: 28203284
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
Welch NM; Jensen DM
Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
[TBL] [Abstract][Full Text] [Related]
3. Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients.
Abdelsameea E; Alsebaey A; Abdel-Samiee M; Abdel-Razek W; Salama M; Waked I
Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1053-1059. PubMed ID: 33307880
[TBL] [Abstract][Full Text] [Related]
4. All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.
Shahid I; Ibrahim MM
Curr Mol Med; 2018; 18(7):409-435. PubMed ID: 30608042
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
6. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C treatment: where are we now?
Burstow NJ; Mohamed Z; Gomaa AI; Sonderup MW; Cook NA; Waked I; Spearman CW; Taylor-Robinson SD
Int J Gen Med; 2017; 10():39-52. PubMed ID: 28255252
[TBL] [Abstract][Full Text] [Related]
9. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
[TBL] [Abstract][Full Text] [Related]
10. The hepatitis C revolution part 1: antiviral treatment options.
Thiagarajan P; Ryder SD
Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
[TBL] [Abstract][Full Text] [Related]
11. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
[TBL] [Abstract][Full Text] [Related]
12. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.
Feld JJ; Jacobson IM; Sulkowski MS; Poordad F; Tatsch F; Pawlotsky JM
Liver Int; 2017 Jan; 37(1):5-18. PubMed ID: 27473533
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy.
Melendez-Mena D; Mendoza-Torres MA; Sedeño-Monge V; García Y García VH; Rivera-García E; Sánchez-Reza L; Baxin Domínguez MDC; Guzmán-Flores B; Martinez-Laguna Y; Coronel Espinoza JM; Galindo-Santiago I; Flores-Alonso JC; Vallejo-Ruiz V; Cortes-Hernandez P; Reyes-Leyva J; Sosa-Jurado F; Santos-López G
PeerJ; 2021; 9():e12051. PubMed ID: 34616602
[TBL] [Abstract][Full Text] [Related]
14. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals.
Alexopoulou A; Karayiannis P
Ann Gastroenterol; 2015; 28(1):55-65. PubMed ID: 25608803
[TBL] [Abstract][Full Text] [Related]
15. Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection.
Nakashima M; Toyoda H; Tada T; Mizuno K; Iio E; Tanaka Y; Sugiyama T; Yoshimura T; Kumada T
Hepatol Res; 2019 May; 49(5):512-520. PubMed ID: 30628746
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals.
Huang Y; Li MH; Hou M; Xie Y
Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):470-479. PubMed ID: 28992878
[TBL] [Abstract][Full Text] [Related]
17. Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience.
Bwa AH; Nangia G; Win STS; Maung ST; Han KAW; Htar SS; Wine LY; Ko WW; Oo MP; Hlaing NKT; Palecki J; Loza BL; Win KM; Reddy R
J Clin Exp Hepatol; 2019; 9(3):283-293. PubMed ID: 31360020
[TBL] [Abstract][Full Text] [Related]
18. Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens.
Younossi Z; Henry L
Aliment Pharmacol Ther; 2015 Mar; 41(6):497-520. PubMed ID: 25616122
[TBL] [Abstract][Full Text] [Related]
19. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?
Holmes JA; Desmond PV; Thompson AJ
J Viral Hepat; 2012 Oct; 19(10):677-84. PubMed ID: 22967098
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.
Sherigar JM; Gayam V; Khan A; Mukhtar O; Arefiev Y; Khalid M; Siddiqui I; Rangaraju AM; Budhathoki N; Mansour M; Guss D; Mohanty SR
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):767-776. PubMed ID: 28346233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
